Publications by authors named "V Fregoni"
Background: Patients with acute venous thromboembolism (VTE) need anticoagulation (AC) therapy for at least 3/6 months (primary treatment); after that period, they should receive a decision on the duration of therapy.
Methods: This study examined the complications occurring during two years of follow-up (FU) in patients with a first VTE who were recruited in 20 clinical centers and had discontinued or prolonged AC. They were included in the START2-POST-VTE prospective observational study.
Article Synopsis
- - The study examined long-term outcomes of venous thromboembolism (VTE) in hospitalized COVID-19 patients compared to those with VTE from other acute medical conditions, involving 278 COVID-19 patients and 300 controls.
- - COVID-19 patients experienced more pulmonary embolism without deep vein thrombosis and had a lower prevalence of chronic inflammatory diseases and previous VTE history compared to the control group.
- - The results indicate that the risk of recurring thrombotic events post-treatment is similarly low for both groups, suggesting that COVID-19-related VTE does not lead to greater long-term complications than VTE from other causes.
Coronavirus disease 2019 (COVID-19) infection causes acute respiratory insufficiency with severe interstitial pneumonia and extrapulmonary complications; in particular, it may predispose to thromboembolic disease. The reported incidence of thromboembolic complications varies from 5 to 30% of cases. We conducted a multicenter, Italian, retrospective, observational study on COVID-19 patients admitted to ordinary wards, to describe the clinical characteristics of patients at admission and bleeding and thrombotic events occurring during the hospital stay.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on breast cancer patients over 65, highlighting their greater risk for side effects from chemotherapy that can lead to early treatment discontinuation, which impacts survival negatively.
- A cohort of 128 women, median age 71, was analyzed for chemotherapy dose changes and side effects, revealing that about 30% faced dose reductions or interruptions.
- Patients who had their chemotherapy altered due to side effects showed worse progression-free survival rates, suggesting that managing side effects is crucial for improving outcomes in this age group.